ストックスクリーナーアプリを入手
0.8342
1.45%
0.0119
前日終値:
$0.8223
開ける：
$0.83
24時間の取引高:
47,152
Relative Volume:
0.02
時価総額：
$4.59M
収益：
-
当期純損益:
$-8.72M
株価収益率:
-0.152
EPS:
-5.4871
ネットキャッシュフロー:
$-5.47M
1週間 パフォーマンス:
+11.15%
1か月 パフォーマンス:
-25.52%
6か月 パフォーマンス:
-54.42%
1年 パフォーマンス:
-72.10%
1日の値動き範囲:
$0.828
$0.88
1週間の範囲:
$0.7505
$0.88
52週間の値動き範囲:
$0.7311
$3.50
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
GLMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.8375 | 4.51M | 0 | -8.72M | -5.47M | -5.4871 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.99 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
800.00 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.91 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.47 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.30 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-05-22 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | 開始されました | Craig Hallum | Buy |
| 2020-01-30 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-12-02 | 開始されました | Canaccord Genuity | Buy |
| 2018-12-12 | 開始されました | B. Riley FBR | Buy |
| 2018-08-02 | 繰り返されました | Maxim Group | Buy |
| 2018-07-13 | 開始されました | Stifel | Buy |
| 2018-07-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-06-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-15 | アップグレード | Maxim Group | Hold → Buy |
| 2018-02-14 | ダウングレード | Maxim Group | Buy → Hold |
| 2018-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-15 | 開始されました | ROTH Capital | Buy |
| 2017-08-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 繰り返されました | Maxim Group | Buy |
| 2016-08-01 | 繰り返されました | Maxim Group | Buy |
| 2016-07-06 | 再開されました | ROTH Capital | Buy |
| 2016-03-28 | 再開されました | H.C. Wainwright | Buy |
| 2015-06-23 | 開始されました | H.C. Wainwright | Buy |
| 2015-05-06 | 開始されました | Sun Trust Rbsn Humphrey | Buy |
すべてを表示
Galmed Pharmaceuticals Ltd (GLMD) 最新ニュース
What drives Galmed Pharmaceuticals Ltd GPH stock priceTrade Execution Strategies & Small Capital Investment Tips - earlytimes.in
EBIT per share of Galmed Pharmaceuticals Ltd. – BER:GPH - TradingView — Track All Markets
Will Galmed Pharmaceuticals Ltd. stock outperform tech sector in 2025Market Sentiment Surveys & Free Rapid Wealth Multiplication - bollywoodhelpline.com
Is Galmed Pharmaceuticals Ltd. stock a defensive play in 2025Evening Star Patterns & High Profit Market Ideas - bollywoodhelpline.com
Downgrade Watch: Why Galmed Pharmaceuticals Ltd stock is seen as undervalued2025 Short Interest & Weekly Breakout Stock Alerts - moha.gov.vn
Financial Survey: Galmed Pharmaceuticals (NASDAQ:GLMD) vs. Qualigen Therapeutics (NASDAQ:QLGN) - Defense World
Will Galmed Pharmaceuticals Ltd. stock benefit from upcoming earnings reportsJuly 2025 Review & Low Drawdown Investment Strategies - Улправда
Aug Selloffs: How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stock2025 Key Lessons & Long-Term Growth Portfolio Plans - Улправда
How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stock2025 Price Action Summary & Daily Stock Trend Watchlist - Улправда
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
How big funds are accumulating Galmed Pharmaceuticals Ltd. (GPH) stockMarket Capitalization Trends & Outperform the Market with Aggressive Picks - Bollywood Helpline
Is Galmed Pharmaceuticals Ltd. (GPH) stock a safe buy pre earningsMarket Trend Review & Weekly Top Gainers Trade List - DonanımHaber
Galmed to present data on Aramchol’s potential in liver cancer By Investing.com - Investing.com Canada
Galmed to present data on Aramchol’s potential in liver cancer - Investing.com
Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation - TipRanks
Galmed Pharmaceuticals’ Aramchol abstract accepted for HEP-DART 2025 presentation - MSN
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PR Newswire
Galmed receives patent for combination therapy in South Korea By Investing.com - Investing.com Nigeria
Can Galmed Pharmaceuticals Ltd. (GPH) stock surprise with quarterly resultsBuy Signal & Weekly Breakout Watchlists - Newser
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - marketscreener.com
Galmed stock rises after patent grant for MASH combo therapy By Investing.com - Investing.com Nigeria
Galmed stock rises after patent grant for MASH combo therapy - Investing.com
Galmed receives patent for combination therapy in South Korea - Investing.com
Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks
Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals - marketscreener.com
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PR Newswire
Can Galmed Pharmaceuticals Ltd. (GPH) stock sustain free cash flowQuarterly Trade Review & Accurate Trade Setup Notifications - Newser
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Is Galmed Pharmaceuticals Ltd. (GPH) stock supported by strong fundamentals2025 EndofYear Setup & Risk Managed Investment Signals - Newser
Is Galmed Pharmaceuticals Ltd. (GPH) stock good for long term investing - Newser
Can Galmed Pharmaceuticals Ltd. (GPH) stock attract ESG investmentsTrade Volume Summary & High Accuracy Investment Signals - Newser
Galmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive Update - MSN
Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position - MSN
Is Galmed Pharmaceuticals Ltd. (GPH) stock positioned for digital growth era2025 Trading Volume Trends & Real-Time Buy Signal Notifications - Newser
Galmed reports $19.2 million cash position, advances Aramchol programs By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook - Investing.com
Galmed Pharmaceuticals Ltd (GLMD) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
大文字化:
|
ボリューム (24 時間):